Development and characterisation of KRASmulti inhibitors for the treatment of KRAS mutant pancreatic ductal adenocarcinoma

被引：0
|
作者：
Tedeschi, Antonio
Schaaf, Otmar
Gmachl, Michael
Herdeis, Lorenz
Rocchetti, Francesca
Popow, Johannes
Schischlik, Fiorella
Gerlach, Daniel
Lipp, Jesse
Broker, Joachim
Mantoulidis, Andreas
Smethurst, Chris
Kessler, Dirk
Boettcher, Jark
Wunberg, Tobias
Santoro, Valeria
Waterson, Alex
Phan, Jason
Little, Andrew
Abbott, Jason
Sun, Qi
Fesik, Stephen
Mcconnell, Darryl
Pearson, Mark A.
Kraut, Norbert
Rudolph, Dorothea
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 02期
关键词：
D O I：
10.1158/1538-7445.PANCA2023-B103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B103
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Therapeutic benefit of targeting ERK in mutant KRAS pancreatic ductal adenocarcinoma
    Hayes, Tikvah K.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Regulation of MYC protein stability by mutant KRAS in pancreatic ductal adenocarcinoma
    Vaseva, Angelina V.
    Blake, Devon R.
    Azam, Salma H.
    Gilbert, Karim T.
    Pecot, Chad V.
    Pearce, Kenneth H.
    Herring, Laura E.
    Graves, Lee M.
    Houghton, Peter J.
    Der, Channing J.
    CANCER RESEARCH, 2017, 77
  • [3] Therapeutic benefit of targeting ERK in mutant KRAS in pancreatic ductal adenocarcinoma (PDAC)
    Hayes, Tikvah K.
    Neel, Nicole F.
    Chenard, Melissa
    Yeh, Jen Jen
    Samatar, Ahmed
    Der, Channing J.
    CANCER RESEARCH, 2013, 73
  • [4] Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
    Chao, Timothy
    Wang, Zi-Xuan
    Bowne, Wilbur B.
    Yudkoff, Clifford J.
    Torjani, Ava
    Swaminathan, Vishal
    Kavanagh, Taylor R.
    Roadarmel, Austin
    Sholevar, Cyrus J.
    Cannaday, Shawnna
    Krampitz, Geoffrey
    Zhan, Tingting
    Gorgov, Eliyahu
    Nevler, Avinoam
    Lavu, Harish
    Yeo, Charles J.
    Peiper, Stephen C.
    Jiang, Wei
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (12) : 1299 - 1309
  • [5] Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study
    Yang, Fan
    He, Yanjie
    Ge, Nan
    Guo, Jintao
    Yang, Fei
    Sun, Siyu
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [6] Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development
    Chu, Nina J.
    Anders, Robert A.
    Fertig, Elana J.
    Cao, Minwei
    Hopkins, Alexander C.
    Keenan, Bridget P.
    Popovic, Aleksandra
    Armstrong, Todd D.
    Jaffee, Elizabeth M.
    Zimmerman, Jacquelyn W.
    CANCER PREVENTION RESEARCH, 2020, 13 (07) : 569 - 582
  • [7] miR-21 inhibition regulates mutant KRAS effector pathways and intercepts development of pancreatic ductal adenocarcinoma
    Zimmerman, Jacquelyn W.
    Burkhart, Richard A.
    Chu, Nina J.
    Fertig, Elana J.
    Jaffee, Elizabeth M.
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
    Rudloff, Udo
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 345 - 368
  • [9] Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma
    Hashimoto, Daisuke
    Arima, Kota
    Yokoyama, Naomi
    Chikamoto, Akira
    Taki, Katsunobu
    Inoue, Risa
    Kaida, Takayoshi
    Higashi, Takaaki
    Nitta, Hidetoshi
    Ohmuraya, Masaki
    Hirota, Masahiko
    Beppu, Toru
    Baba, Hideo
    PANCREAS, 2016, 45 (08) : 1111 - 1114
  • [10] Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
    Rajpurohit, Tarun
    Bhattacharya, Sankha
    CURRENT MOLECULAR PHARMACOLOGY, 2022, 15 (07) : 904 - 928
12345